Physician Readiness for Pharmacogenomics and Genomic-Guided Prescribing: A Cross-Sectional Study at Government College University, Faisalabad, Pakistan
Keywords:
shared decision-making; decision aids; cardiovascular risk; primary prevention; randomized controlled trialAbstract
Background: Pharmacogenomics (PGx) enables genotype-guided prescribing to improve drug safety and efficacy; however, implementation in low- and middle-income countries remains limited. Physician readiness—encompassing knowledge, attitudes, competence, practice behavior, and perceived barriers—is critical for clinical integration. Objective: To evaluate PGx knowledge, attitudes, self-efficacy, practice patterns, barriers, and predictors of readiness among physicians affiliated with Government College University (GCU), Faisalabad, Pakistan. Methods: A cross-sectional survey of 137 physicians was conducted using a structured instrument assessing objective knowledge (0–15), attitudes (1–5), self-efficacy (1–5), practice index (0–6), barrier score (1–5), and composite readiness (0–100). “Ready” was defined as ≥65. Associations were examined using t-tests, chi-square tests, and multivariable logistic regression with adjusted odds ratios (OR) and 95% confidence intervals (CI). Results: Mean readiness was 61.2±12.8, with 32.1% classified as ready. Formal PGx training (23.4% prevalence) was associated with higher knowledge (10.8±2.0 vs 8.1±2.3; p<0.001; g=1.20) and readiness (72.0±10.0 vs 58.0±12.0; p<0.001). Training independently predicted readiness (OR=3.6; 95% CI 1.5–8.7; p=0.004), as did knowledge of local ordering pathways (OR=4.2; 95% CI 1.8–10.0; p=0.001), while higher barrier scores reduced readiness (OR=0.55 per unit increase; p=0.009). Conclusion: Physician readiness for PGx at GCU Faisalabad is moderate but suboptimal; structured education and system-level infrastructure are essential to translate favorable attitudes into genomic-guided prescribing.
References
1. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343–350.
2. Caudle KE, Klein TE, Hoffman JM, Muller DJ, Whirl-Carrillo M, Gong L, et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Clin Pharmacol Ther. 2014;95(4):376–382.
3. Crews KR, Hicks JK, Pui CH, Relling MV, Evans WE. Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther. 2012;91(2):321–326.
4. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793–795.
5. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15–19.
6. Hicks JK, Dunnenberger HM, Gumpper KF, Haidar CE, Hoffman JM. Integrating pharmacogenomics into electronic health records with clinical decision support. Clin Pharmacol Ther. 2015;97(5):510–520.
7. Dunnenberger HM, Crews KR, Hoffman JM, Caudle KE, Broeckel U, Howard SC, et al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Am J Med Genet C Semin Med Genet. 2014;166C(1):79–88.
8. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92(4):414–417.
9. Haga SB, Burke W, Agans R. Primary-care physicians’ access to genetic specialists: an impediment to the routine use of pharmacogenetic testing? Genet Med. 2012;14(10):872–879.
10. Stanek EJ, Sanders CL, Taber KA, Khalid M, Patel A, Verbrugge RR, et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Am J Health Syst Pharm. 2012;69(18):1539–1545.
11. Luzum JA, Pakyz RE, Elsey AR, Haidar CE, Peterson JF, Whirl-Carrillo M, et al. The pharmacogenomics research network translational pharmacogenetics program: outcomes and metrics of pharmacogenetic implementation across diverse healthcare systems. Clin Pharmacol Ther. 2017;101(2):185–192.
12. O’Donnell PH, Danahey K, Jacobs M, Wadhwa NR, Yuen S, Bush A, et al. Adoption of a clinical pharmacogenomics implementation program during outpatient care—initial results of the University of Chicago “1200 Patients Project”. Genet Med. 2019;21(7):159–169.
13. Schildcrout JS, Denny JC, Bowton E, Gregg W, Pulley JM, Basford MA, et al. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin Pharmacol Ther. 2012;92(2):235–242.
14. Volpi S, Bult CJ, Chisholm RL, Deverka PA, Ginsburg GS, Haidar CE, et al. Research directions in the clinical implementation of pharmacogenomics: an overview of US programs and challenges. Front Pharmacol. 2018;9:1159
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Bint-e-Kulsoom, Amir Nazir (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright is retained by the Author(s). Published in JPMHR under the Creative Commons Attribution 4.0 International License (CC BY 4.0). Unrestricted reuse is permitted with proper attribution to the author(s) and source.
